Health Catalyst
Market Cap
US$1.4b
Last Updated
2020/09/28 05:42 UTC
Data Sources
Company Financials +
Executive Summary
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Mediocre balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has Health Catalyst's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HCAT has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
4.9%
HCAT
2.4%
US Healthcare Services
-0.8%
US Market
1 Year Return
13.9%
HCAT
64.5%
US Healthcare Services
13.8%
US Market
Return vs Industry: HCAT underperformed the US Healthcare Services industry which returned 64.5% over the past year.
Return vs Market: HCAT matched the US Market which returned 13.8% over the past year.
Shareholder returns
| HCAT | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.9% | 2.4% | -0.8% |
| 30 Day | 17.8% | -0.3% | -5.7% |
| 90 Day | 23.5% | 16.9% | 8.6% |
| 1 Year | 13.9%13.9% | 65.0%64.5% | 16.4%13.8% |
| 3 Year | n/a | 101.5%100.0% | 36.9%27.8% |
| 5 Year | n/a | 164.7%161.9% | 85.0%64.2% |
Price Volatility Vs. Market
How volatile is Health Catalyst's share price compared to the market and industry in the last 5 years?
Simply Wall St News
7 hours ago | Simply Wall St
The Health Catalyst (NASDAQ:HCAT) Share Price Has Gained 14% And Shareholders Are Hoping For More1 month ago | Simply Wall St
Health Catalyst, Inc. (NASDAQ:HCAT) Shares Could Be 49% Below Their Intrinsic Value Estimate2 months ago | Simply Wall St
Health Check: How Prudently Does Health Catalyst (NASDAQ:HCAT) Use Debt?Valuation
Is Health Catalyst undervalued compared to its fair value and its price relative to the market?
47.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HCAT ($36.03) is trading below our estimate of fair value ($69.07)
Significantly Below Fair Value: HCAT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HCAT is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.
PE vs Market: HCAT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HCAT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HCAT is overvalued based on its PB Ratio (6x) compared to the US Healthcare Services industry average (5.2x).
Next Steps
Future Growth
How is Health Catalyst forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
11.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HCAT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HCAT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HCAT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HCAT's revenue (17.6% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: HCAT's revenue (17.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HCAT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Health Catalyst performed over the past 5 years?
65.1%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: HCAT is currently unprofitable.
Growing Profit Margin: HCAT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HCAT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare HCAT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HCAT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.8%).
Return on Equity
High ROE: HCAT has a negative Return on Equity (-34.35%), as it is currently unprofitable.
Next Steps
Financial Health
How is Health Catalyst's financial position?
Financial Position Analysis
Short Term Liabilities: HCAT's short term assets ($397.0M) exceed its short term liabilities ($50.2M).
Long Term Liabilities: HCAT's short term assets ($397.0M) exceed its long term liabilities ($182.2M).
Debt to Equity History and Analysis
Debt Level: HCAT's debt to equity ratio (69.9%) is considered high.
Reducing Debt: Insufficient data to determine if HCAT's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HCAT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HCAT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Health Catalyst current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HCAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HCAT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HCAT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HCAT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HCAT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.0yrs
Average management tenure
CEO
Dan Burton (45 yo)
7.92yrs
Tenure
US$3,519,722
Compensation
Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has many years of strate ...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD3.52M) is about average for companies of similar size in the US market ($USD4.61M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.92yrs | US$3.52m | 0.019% $ 270.3k | |
| Chief Operating Officer | 1.92yrs | US$2.53m | 0.016% $ 225.4k | |
| Chief Technology Officer | 1.58yrs | US$3.30m | 0.41% $ 5.9m | |
| Co-Founder & Senior VP | 12.67yrs | no data | 3.59% $ 51.4m | |
| Co-Founder & Chief Learning Officer | 12.67yrs | no data | no data | |
| Chief Financial Officer | 3yrs | US$1.70m | 0.25% $ 3.6m | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| General Counsel & Secretary | 4.67yrs | no data | 0.10% $ 1.4m | |
| Chief Communications and Diversity | 1.33yrs | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Executive Vice President - Sales | no data | no data | no data | |
| Senior Vice President of Marketing | 1.33yrs | no data | no data |
3.0yrs
Average Tenure
54.5yo
Average Age
Experienced Management: HCAT's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.92yrs | US$3.52m | 0.019% $ 270.3k | |
| Director | 0.33yr | no data | no data | |
| Independent Director | 5.67yrs | US$194.05k | 0.21% $ 3.1m | |
| Independent Director | 8yrs | US$42.25k | 0.71% $ 10.2m | |
| Independent Director | 6.33yrs | US$173.38k | 0.16% $ 2.3m | |
| Independent Director | 0.67yr | no data | no data | |
| Independent Director | 9yrs | US$160.01k | 0.12% $ 1.8m | |
| Independent Director | 4.42yrs | US$37.50k | 0% $ 0 | |
| Independent Director | 3.33yrs | US$46.45k | 0% $ 0 | |
| Director | 2.67yrs | US$35.00k | 0.014% $ 196.2k | |
| Independent Director | 0.67yr | no data | no data |
4.4yrs
Average Tenure
58yo
Average Age
Experienced Board: HCAT's board of directors are considered experienced (4.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.8%.
Top Shareholders
Company Information
Health Catalyst, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Health Catalyst, Inc.
- Ticker: HCAT
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$1.431b
- Shares outstanding: 39.71m
- Website: https://www.healthcatalyst.com
Number of Employees
Location
- Health Catalyst, Inc.
- 3165 Millrock Drive
- Suite 400
- Salt Lake City
- Utah
- 84121
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HCAT | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jul 2019 |
| 2YP | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2019 |
Biography
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/28 05:42 |
| End of Day Share Price | 2020/09/25 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.